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Program OVERVIEW
Saturday, May 3  Room Time 
Registration  Level 2/South Lobby A  7am–6pm
ARVO/ISIE Imaging Conference† S 310  8am–5:30pm
ARVO Education Courses †
 Metabolic Networks in the Aging Eye S 230GH 8:30am–12pm
 Diabetic Retinopathy S 210A-C 8:30am–4:30pm
 Cell Therapy in Ocular Disease S 230A-D  8:30am–4:30pm
 Corneal Biomechanics S 210DE 8:30am–4:30pm
 Tissue Diagnosis in Ophthalmology S 230EF 8:30am–4:30pm
 Telehealth Methods for Eye Disease S 230GH 1–4:30pm
ARVO Foundation/Dowling Society Gala† Hyatt Regency Orlando (Peabody) 7–10pm 
Sunday, May 4
Registration  Level 2/South Lobby A 7am–6pm
ARVO Central Level 1/South Hall A 7am–6pm
Exhibits/Optional Exhibit Hours** Level 1/South Hall A 7:30–9am**/9am–4pm (all exhibits open)/4–5pm**
Symposia  See Program 8:30–10:30am
Posters/All Posters Session Level 1/South Hall A 8:30–10:15am/10:45–11:45am*/1:30–3:15pm/3:15–5pm
Opening Keynote Session – Barry Marshall, Nobel Laureate Level 1/South Hall B 12noon–1:15pm
Pizza with the Experts† S 210A-C 1:30–3pm
EVER/ARVO Workshop S 320GH 1:30–3pm
SIGs/Workshops See Program 1:30–3pm
Multidisciplinary Ophthalmic Imaging Group S 210DE 1:30–3pm
Papers  See Program 3:15–5pm 
Basic Clinical Lecture Level 1/South Hall B 5:15–7:15pm
ARVO Social featuring ARVO Rocks!† Universal Studios Florida® 7:30am–10:30pm
Monday, May 5
Registration  Level 2/South Lobby A 7am–6pm
ARVO Central Level 1/South Hall A 7am–6pm
Exhibits/Optional Exhibit Hours** Level 1/South Hall A 7:30–9am**/9am–4pm (all exhibits open)/4–5:30pm**
NAEVR Briefing S 329 7:30–8:30am
Posters/All Posters Session Level 1/South Hall A 8:30–10:15am/11am –12:45pm/2:45–3:45pm*/3:45–5:30pm
Papers/Minisymposia See Program 8:30–10:15am/11am-12:45pm/3:45–5:30pm
Section Business Meetings See Program 10:15–10:55am
SIGs/Workshops See Program 1–2:30pm
Genetics Group S 210DE 1–2:30pm 
China–US Networking Forum S 210A-C 1–2:30pm
Proctor Award Lecture Level 1/South Hall B 5:45–6:30pm
Weisenfeld Award Lecture Level 1/South Hall B 6:45–7:30pm
Student/Trainee Social Hilton Orlando, Fountain Plaza 7:30–9pm
Tuesday, May 6
Registration  Level 2/South Lobby A 7am–6pm
ARVO Central Level 1/South Hall A 7am–6pm
Exhibits/Optional Exhibit Hours** Level 1/South Hall A 7:30–9am**/9am–4pm (all exhibits open)/4–5:30pm**
Posters/All Posters Session Level 1/South Hall A 8:30–10:15am/11am –12:45pm/2:45–3:45pm*/3:45–5:30pm
Papers/Minisymposia See Program 8:30–10:15am/11am-12:45pm/3:45–5:30pm
Research Grant Administrators Program S319 8am–5pm
ARVO Foundation WEAVR Silent Auction Level 1/South Hall A 9:30am–3:45pm
General Business Meeting S 230GH 10:15–10:55am
SIGs/Workshops See Program 1–2:30pm
Low Vision Group S 210DE  1–2:30pm 
ARVO Foundation WEAVR Luncheon† Level 1/South Hall B 1–2:30pm 
Where are the Women? Exploring Roles in ARVO S 320AB 5:30–7pm
Wednesday, May 7
Registration  Level 2/South Lobby A 7am–6pm
ARVO Central Level 1/South Hall A 7am–6pm
Breakfast with the Experts†  S 210A-C 7–8:30am 
Exhibits/Optional Exhibit Hours** Level 1/South Hall A 7:30–9am**/9am–4pm (all exhibits open)/4–5:30pm**
Posters/All Posters Session Level 1/South Hall A 8:30–10:15am/11am –12:45pm/2:45–3:45pm*/3:45–5:30pm
Papers/Minisymposia See Program 8:30–10:15am/11am-12:45pm/3:45–5:30pm
NEI/Audacious Goals Update  Level 1/South Hall B 10:15–10:55am
SIGs/Workshops See Program 1–2:30pm
Nanotechnology and Regenerative Medicine Group S 210DE 1–2:30pm 
Cogan Award Lecture Level 1/South Hall B 5:45–6:30pm
Friedenwald Award Lecture Level 1/South Hall B 6:45–7:30pm
Classical Concert Hyatt Regency Orlando (Peabody) 8–10pm
ARVO Karaoke Night ICEBAR Orlando 9pm–12midnight
Thursday, May 8
Registration  Level 2/South Lobby A 7am–2pm
ARVO Central Level 1/South Hall A 7am–2pm
Symposia  See Program 8:30–10:30am
Posters/All Posters Session Level 1/South Hall A 8:30–10:15am/10:45–11:45am*/12noon–1:45pm
Denver Kickoff Reception Level 1/South Hall A 10:45–11:45am
Papers  See Program 12noon–1:45pm
ARVO/Alcon Keynote Series — Jean Bennett, MD, PhD, FARVO Level 1/South Hall B 2–3:15pm
† Separate registration required  * All Posters— all first authors will be present for the first hour 
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n ARVO Commercial Relationships Policy 
n  Commercial Relationships Index
n  Statement on Registering Clinical Trials
n  Clinical Trials Index
© 2014 by the Association for Research in Vision and Ophthalmology, Inc. All rights 
reserved. Permission to republish any part of this book must be obtained in writing 
from the ARVO Senior Director of Communications and Business Strategies, prior 
to publication. Contact Joanne Olson at jolson@arvo.org.
Children in the Convention Center
Children under 18 years old must be accompanied by a parent or guardian at all 
times. Parents/guardians who bring children into paper sessions must remove them 
immediately if they become disruptive. Children are not allowed to accompany 
parents/guardians in sessions/events where tickets are required or food is provided, 
except events for which children’s tickets are available for purchase. Under no 
circumstances are children permitted in the exhibit hall during set-up or dismantle 
times. 
Program Summary
The Program Summary is distributed onsite to all ARVO Annual Meeting 
participants. Abstracts are referred to in the Program Summary by program number 
(not page number) and session number. Abstracts may be viewed and printed 
either individually or by session at arvo.org/Annual_Meeting/Program. Additional 
program search tools linked from arvo.org/Annual_Meeting/Program:
n ARVO 2014 Online Planner: All the search functionality of the Abstract Search, 
plus you can build your schedule and sync with the ARVO 2014 Mobile App on 
your device.
n ARVO 2014 Mobile App: The ARVO Online Planner on your device – offers 
complete search functionality and the ability to continue planning your personal 
schedule in the Online Planner on-the-go. 
n ARVO 2014 Abstract Search: Search the complete 2014 program by keyword, 
author, moderator and more. Not recommended for building an itinerary; it will not 
sync with the Online Planner or Mobile App.
Use of recording/photography/audiotape/video equipment: Recording by 
any means (photographing, audiotaping, videotaping) of any presentations or 
sessions at any ARVO Meeting is prohibited, except by an ARVO-authorized agent 
for official purposes or by First Authors who want to photograph their own poster 
presentations. Violators risk confiscation of their equipment and/or dismissal from 
the Annual Meeting as deemed appropriate by ARVO.
Commercial Relationships Policy: Presenters must state and display all 
applicable commercial relationships. For more information on this important policy, 
refer to the Commercial Relationships Index at arvo.org/amindices.
Clinical Trials Registration Policy: All clinical trials that will be reported in ARVO 
Annual Meeting abstracts must be registered on a publicly available database. The 
required acknowledgement of the First Author, acting as the authorized agent for 
all authors, certifies that any research presented in the abstract that reports on a 
clinical trial must be registered, and the registration location and number must be 
included on the abstract, in compliance with the ARVO Statement on Registering 
Clinical Trials, arvo.org/clinicaltrials. For more information on this policy, refer to 
the Clinical Trials Registration Index at arvo.org/amindices.
Important Policies
Disclaimer
The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 
online program materials and print publications aim to promote vision research 
and scientific discourse for educational purposes. ARVO accepts no responsibility 
for any products, presentations, opinions, statements or positions expressed; and 
inclusion of such material within the Meeting, the publications or posted online does 
not constitute an endorsement by ARVO.
Photography Release
By attending the ARVO Annual Meeting, attendees agree to allow their names, 
likenesses and images either in audio, photographic or video format recorded onsite 
to be used by ARVO and the ARVO Foundation for Eye Research for educational 
and promotional purposes.
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Indication
JETREA® (ocriplasmin) Intravitreal Injection, 2.5 mg/mL, 
is a proteolytic enzyme indicated for the treatment of  
symptomatic vitreomacular adhesion (VMA).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
• A decrease of ≥3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA® and 
3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression 
of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
• Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage, and increased intraocular 
pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, 
intraocular inflammation occurred in 7.1% of patients injected with JETREA® vs 3.7% of patients injected with vehicle. Most of the 
post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA®, 
it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
• Potential for lens subluxation.
• In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA® group and 1.6% in the vehicle group, 
while the incidence of retinal tear (without detachment) was 1.1% in the JETREA® group and 2.7% in the vehicle group. Most 
of these events occurred during or after vitrectomy in both groups.
• Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA®. 
In approximately half of these dyschromatopsia cases, there were also electroretinographic (ERG) changes reported (a- and 
b-wave amplitude decrease).
Adverse Reactions
• The most commonly reported reactions (≥5%) in patients treated with JETREA® were vitreous  
floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced  
visual acuity, visual impairment, and retinal edema.
TAKE IMMEDIATE ACTION 
WITH
The FIRST AND ONLY pharmacologic treatment for symptomatic VMA
JETREA®
Please see Brief Summary of full Prescribing Information on adjacent page.
© 2014 ThromboGenics, Inc. All rights reserved. ThromboGenics, Inc., 101 Wood Avenue South, Suite 610, Iselin, NJ 08830 – USA. 
JETREA and the JETREA logo, JETREA CARE and the JETREA CARE logo, and THROMBOGENICS and the THROMBOGENICS logo are trademarks or registered trademarks of ThromboGenics NV.  03/14 OCRVMA0196 
VISIT JETREACARE.COM OR SCAN 
QR CODE FOR REIMBURSEMENT 
AND ORDERING INFORMATION
JETREA.COM
Permanent J-Code for JETREA® 
NOW AVAILABLE
Effective January 1, 2014
J7316
VISIT US AT  
BOOTH #818
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BRIEF SUMMARY OF FULL PRESCRIBING 
INFORMATION
Please see the JETREA® package insert for full 
Prescribing Information.
1  INDICATIONS AND USAGE
JETREA is a proteolytic enzyme indicated for the treatment 
of symptomatic vitreomacular adhesion.
2  DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
Must be diluted before use. For single-use ophthalmic 
intravitreal injection only. JETREA must only be 
administered by a qualified physician.  
2.2 Dosing
The recommended dose is 0.125 mg (0.1 mL of the diluted 
solution) administered by intravitreal injection to the 
affected eye once as a single dose.
2.3 Preparation for Administration
Remove the vial (2.5 mg/mL corresponding to 0.5 mg 
ocriplasmin) from the freezer and allow to thaw at room 
temperature (within a few minutes). Once completely 
thawed, remove the protective polypropylene flip-off cap 
from the vial. The top of the vial should be disinfected with 
an alcohol wipe. Using aseptic technique, add 0.2 mL of 
0.9% w/v Sodium Chloride Injection, USP (sterile, 
preservative-free) into the JETREA vial and gently swirl the 
vial until the solutions are mixed.
Visually inspect the vial for particulate matter. Only a clear, 
colorless solution without visible particles should be used. 
Using aseptic technique, withdraw all of the diluted solution 
using a sterile #19 gauge needle (slightly tilt the vial to ease 
withdrawal) and discard the needle after withdrawal of 
the vial contents. Do not use this needle for the intravitreal 
injection. 
Replace the needle with a sterile #30 gauge needle, 
carefully expel the air bubbles and excess drug from the 
syringe and adjust the dose to the 0.1 mL mark on the 
syringe (corresponding to 0.125 mg ocriplasmin). THE 
SOLUTION SHOULD BE USED IMMEDIATELY AS IT CONTAINS 
NO PRESERVATIVES. Discard the vial and any unused 
portion of the diluted solution after single use.
2.4 Administration and Monitoring
The intravitreal injection procedure should be carried out 
under controlled aseptic conditions, which include the use 
of sterile gloves, a sterile drape and a sterile eyelid speculum 
(or equivalent). Adequate anesthesia and a broad spectrum 
microbiocide should be administered according to standard 
medical practice.
The injection needle should be inserted 3.5 - 4.0 mm 
posterior to the limbus aiming towards the 
center of the vitreous cavity, avoiding the 
horizontal meridian. The injection volume of 
0.1 mL is then delivered into the mid-vitreous.
Immediately following the intravitreal injection, patients 
should be monitored for elevation in intraocular pressure. 
Appropriate monitoring may consist of a check for 
perfusion of the optic nerve head or tonometry. If required, 
a sterile paracentesis needle should be available.
Following intravitreal injection, patients should be 
instructed to report any symptoms suggestive of 
endophthalmitis or retinal detachment (e.g., eye pain, 
redness of the eye, photophobia, blurred or decreased 
vision) without delay [see Patient Counseling Information].
Each vial should only be used to provide a single injection 
for the treatment of a single eye. If the contralateral eye 
requires treatment, a new vial should be used and the 
sterile field, syringe, gloves, drapes, eyelid speculum, and 
injection needles should be changed before JETREA is 
administered to the other eye, however, treatment with 
JETREA in the other eye is not recommended within 7 days 
of the initial injection in order to monitor the post-injection 
course including the potential for decreased vision in the 
injected eye.
Repeated administration of JETREA in the same eye is not 
recommended [see Nonclinical Toxicology].
After injection, any unused product must be discarded.
No special dosage modification is required for any of the 
populations that have been studied (e.g. gender, elderly).
3  DOSAGE FORMS AND STRENGTHS
Single-use glass vial containing JETREA 0.5 mg in 0.2 mL 
solution for intravitreal injection (2.5 mg/mL).
4  CONTRAINDICATIONS
None
5  WARNINGS AND PRECAUTIONS
5.1 Decreased Vision
A decrease of ≥ 3 line of best corrected visual acuity (BCVA) 
was experienced by 5.6% of patients treated with JETREA 
and 3.2% of patients treated with vehicle in the controlled 
trials [see Clinical Studies].
The majority of these decreases in vision were due to 
progression of the condition with traction and many 
required surgical intervention. Patients should be 
monitored appropriately [see Dosage and Administration].
5.2 Intravitreal Injection Procedure Associated 
Effects
Intravitreal injections are associated with intraocular 
inflammation / infection, intraocular hemorrhage and increased 
intraocular pressure (IOP). In the controlled trials, intraocular 
inflammation occurred in 7.1% of patients injected with 
JETREA vs. 3.7% of patients injected with vehicle. Most of 
the post-injection intraocular inflammation events were 
mild and transient. Intraocular hemorrhage occurred in 
2.4% vs. 3.7% of patients injected with JETREA vs. vehicle, 
respectively. Increased intraocular pressure occurred in 
4.1% vs. 5.3% of patients injected with JETREA vs. vehicle, 
respectively.
5.3 Potential for Lens Subluxation
One case of lens subluxation was reported in a patient who 
received an intravitreal injection of 0.175 mg (1.4 times 
higher than the recommended dose). Lens subluxation was 
observed in three animal species (monkey, rabbit, minipig) 
following a single intravitreal injection that achieved 
vitreous concentrations of ocriplasmin 1.4 times higher 
than achieved with the recommended treatment dose. 
Administration of a second intravitreal dose in monkeys, 
28 days apart, produced lens subluxation in 100% of the 
treated eyes [see Nonclinical Toxicology]. 
5.4 Retinal Breaks
In the controlled trials, the incidence of retinal detachment 
was 0.9% in the JETREA group and 1.6% in the vehicle 
group, while the incidence of retinal tear (without 
detachment) was 1.1% in the JETREA group and 2.7% in 
the vehicle group. Most of these events occurred during 
or after vitrectomy in both groups. The incidence of retinal 
detachment that occurred pre-vitrectomy was 0.4% in 
the JETREA group and none in the vehicle group, while 
the incidence of retinal tear (without detachment) that 
occurred pre-vitrectomy was none in the JETREA group and 
0.5% in the vehicle group.
5.5 Dyschromatopsia
Dyschromatopsia (generally described as yellowish vision) 
was reported in 2% of all patients injected with JETREA. In 
approximately half of these dyschromatopsia cases there 
were also electroretinographic (ERG) changes reported 
(a- and b-wave amplitude decrease).
6  ADVERSE REACTIONS
The following adverse reactions are described below and 
elsewhere in the labeling:
• Decreased Vision [see Warnings and Precautions]
• Intravitreal Injection Procedure Associated Effects 
[see Warnings and Precautions and Dosage and 
Administration]
• Potential for Lens Subluxation [see Warnings  
and Precautions]
• Retinal Breaks [see Warnings and Precautions and 
Dosage and Administration] 
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying 
conditions, adverse reaction rates in one clinical trial of a 
drug cannot be directly compared with rates in the clinical 
trials of the same or another drug and may not reflect the 
rates observed in practice.
Approximately 800 patients have been treated with an 
intravitreal injection of JETREA. Of these, 465 patients 
received an intravitreal injection of ocriplasmin 0.125 mg 
(187 patients received vehicle) in the 2 vehicle-controlled 
studies (Study 1 and Study 2).
The most common adverse reactions (incidence 5% - 20% 
listed in descending order of frequency) in the vehicle- 
controlled clinical studies were: vitreous floaters, 
conjunctival hemorrhage, eye pain, photopsia, blurred 
vision, macular hole, reduced visual acuity, visual 
impairment, and  retinal edema.
Less common adverse reactions observed in the studies at 
a frequency of 2% - < 5% in patients treated with JETREA 
included macular edema, increased intraocular pressure, 
anterior chamber cell, photophobia, vitreous detachment, 
ocular discomfort, iritis, cataract, dry eye, metamorphopsia, 
conjunctival hyperemia, and retinal degeneration.
Dyschromatopsia was reported in 2% of patients injected 
with JETREA, with the majority of cases reported from 
two uncontrolled clinical studies. In approximately 
half of these dyschromatopsia cases there were also 
electroretinographic (ERG) changes reported (a- and 
b-wave amplitude decrease).
6.2 Immunogenicity
As with all therapeutic proteins, there is potential for 
immunogenicity. Immunogenicity for this product has not 
been evaluated.
8  USE IN SPECIFIC POPULATIONS
8.1 Pregnancy:  Teratogenic Effects
Pregnancy Category C. Animal reproduction studies 
have not been conducted with ocriplasmin. There are no 
adequate and well-controlled studies of ocriplasmin in 
pregnant women. It is not known whether ocriplasmin 
can cause fetal harm when administered to a pregnant 
woman or can affect reproduction capacity. The systemic 
exposure to ocriplasmin is expected to be low after 
intravitreal injection of a single 0.125 mg dose. Assuming 
100% systemic absorption (and a plasma volume 
of 2700 mL), the estimated plasma concentration is 
46 ng/mL. JETREA should be given to a pregnant woman 
only if clearly needed. 
8.3 Nursing Mothers
It is not known whether ocriplasmin is excreted in human 
milk. Because many drugs are excreted in human milk, 
and because the potential for absorption and harm to 
infant growth and development exists, caution should 
be exercised when JETREA is administered to a nursing 
woman. 
8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been 
established.
8.5 Geriatric Use
In the clinical studies, 384 and 145 patients were ≥ 65 years 
and of these 192 and 73 patients were ≥ 75 years in the 
JETREA and vehicle groups respectively. No significant 
differences in efficacy or safety were seen with increasing 
age in these studies.
10  OVERDOSAGE
The clinical data on the effects of JETREA overdose are 
limited. One case of accidental overdose of 0.250 mg 
ocriplasmin (twice the recommended dose) was reported 
to be associated with inflammation and a decrease in visual 
acuity.
13  NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment 
of Fertility
No carcinogenicity, mutagenicity or reproductive and 
developmental toxicity studies were conducted with 
ocriplasmin.
13.2 Animal Toxicology and/or Pharmacology
The ocular toxicity of ocriplasmin after a single 
intravitreal dose has been evaluated in rabbits, 
monkeys and minipigs. Ocriplasmin induced an 
inflammatory response and transient ERG changes in 
rabbits and monkeys, which tended to resolve over 
time. Lens subluxation was observed in the 3 species at 
ocriplasmin concentrations in the vitreous at or above 
41 mcg/mL, a concentration 1.4-fold above the intended 
clinical concentration in the vitreous of 29 mcg/mL. 
Intraocular hemorrhage was observed in rabbits and 
monkeys.
A second intravitreal administration of ocriplasmin 
(28 days apart) in monkeys at doses of 75 mcg/eye 
(41 mcg/mL vitreous) or 125 mcg/eye (68 mcg/mL 
vitreous) was associated with lens subluxation in all 
ocriplasmin treated eyes. Sustained increases in IOP 
occurred in two animals with lens subluxation. 
Microscopic findings in the eye included vitreous 
liquefaction, degeneration/disruption of the hyaloideo- 
capsular ligament (with loss of ciliary zonular fibers), lens 
degeneration, mononuclear cell infiltration of the vitreous, 
and vacuolation of the retinal inner nuclear cell layer. 
These doses are 1.4-fold and 2.3-fold the intended clinical 
concentration in the vitreous of 29 mcg/mL, respectively.
14  CLINICAL STUDIES
The efficacy and safety of JETREA was demonstrated 
in two multicenter, randomized, double masked, 
vehicle-controlled, 6 month studies in patients 
with symptomatic vitreomacular adhesion 
(VMA). A total of 652 patients (JETREA 464, 
vehicle 188) were randomized in these 2 studies. 
Randomization was 2:1 (JETREA:vehicle) in Study 1 and 
3:1 in Study 2.
Patients were treated with a single injection of JETREA or 
vehicle. In both of the studies, the proportion of patients 
who achieved VMA resolution at Day 28 (i.e., achieved 
success on the primary endpoint) was significantly higher 
in the ocriplasmin group compared with the vehicle group 
through Month 6.   
 
The number of patients with at least 3 lines increase in 
visual acuity was numerically higher in the ocriplasmin 
group compared to vehicle in both trials, however, the 
number of patients with at least a 3 lines decrease in visual 
acuity was also higher in the ocriplasmin group in one of the 
studies (Table 1 and Figure 1).
Table 1: Categorical Change from Baseline in 
BCVA at Month 6, Irrespective of Vitrectomy 
(Study 1 and Study 2)
Figure 1: Percentage of Patients with Gain or 
Loss of ≥ 3 Lines of BCVA at Protocol-Specified 
Visits
16  HOW SUPPLIED/STORAGE AND HANDLING
Each vial of JETREA contains 0.5 mg ocriplasmin in 0.2 mL 
citric-buffered solution (2.5 mg/mL). JETREA is supplied in 
a 2 mL glass vial with a latex free rubber stopper. Vials are 
for single use only.  
Storage
Store frozen at or below  -4˚F ( -20˚C). Protect the vials 
from light by storing in the original package until time of 
use.
17  PATIENT COUNSELING INFORMATION
In the days following JETREA administration, patients 
are at risk of developing intraocular inflammation/
infection. Advise patients to seek immediate care from an 
ophthalmologist if the eye becomes red, sensitive to light, 
painful, or develops a change in vision [see Warnings and 
Precautions].
Patients may experience temporary visual impairment after 
receiving an intravitreal injection of JETREA [see Warnings 
and Precautions]. Advise patients to not drive or operate 
heavy machinery until this visual impairment has resolved. 
If visual impairment persists or decreases further, advise 





















N=219 N=107 (95% CI)
≥ 3 line Improvement in BCVA
Month 6 28 (12.8%) 9 (8.4%) 4.4 (-2.5, 11.2)
> 3 line Worsening in BCVA
Month 6 16 (7.3%) 2 (1.9%) 5.4 (1.1, 9.7)
Study 2
JETREA Vehicle Difference
N=245 N=81 (95% CI)
≥ 3 line Improvement in BCVA
Month 6 29 (11.8%) 3 (3.8%) 8.1 (2.3, 13.9)
> 3 line Worsening in BCVA
Month 6 10 (4.1%) 4 (5.0%) -0.9 (-6.3, 4.5)
Manufactured for: 
ThromboGenics, Inc.
101 Wood Avenue South, 6th Floor 
Iselin, NJ 08830
U.S. License Number: 1866
©2013, ThromboGenics, Inc. All rights reserved.
Version 1.0
Initial U.S. Approval: 2012 
ThromboGenics U.S. patents: 7,445,775; 7,547,435; 7,914,783 
and other pending patents.
JETREA and the JETREA logo are trademarks or registered 
trademarks of ThromboGenics NV in the United States, 
European Union, Japan, and other countries. 
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4128 — A0116 Multiplexing Prism: A novel optical element 
for visual field expansion. Eli Peli. 1Ophthalmology, Schepens 
Eye Research Institute, Boston, MA; 2Ophthalmology, MEE, 
Harvard Medical School, Boston, MA *CR
The Program Summary provides a summary of the ARVO 2014 
Annual Meeting Scientific Program and information about 
other Meeting events and activities. Abstracts are not included. 
Abstracts are available online for viewing and printing. See below 
for details.
 The scientific program is organized chronologically by day, 
session time and program number. All sessions scheduled within 
the same time slot are listed together (see thumb index at the side 
of each page).
 A Program Schedule-at-a-Glance is included for each day to 
provide a quick view of the scheduled paper and poster sessions, 
symposia, award lectures, business meetings, workshops and spe-
cial interest groups (SIGs). These program schedules are located 
at the beginning of each scientific program day.
 Page headers include the day, type of session and the program 
number range on each page. 
Indices
There are four indices to assist you in locating sessions, modera-
tors and presentations.
n  Author Index — All authors are listed alphabetically by last 
name. Boldface type is used to indicate the program number 
and poster board number of the abstract for which the author 
is First (Presenting) Author. Bold and italic type indicates a 
symposium presentation. This index is located in the back of 
this book.
n  Moderator Index — This is a listing of the session modera-
tors alphabetically by last name. Included are the moderator’s 
name, session day, date, time, location, title and Commercial 
Relationships Disclosure, if applicable. This index is located in 
the back of this book. 
n  Clinical Trial Registration Index (online only) —This is 
a listing by program number of the clinical trial registration 
information for each applicable presentation as indicated at the 
time of abstract submission. See ARVO Statement on Register-
ing Clinical Trials in the Index. This index can be found online 
at arvo.org/2013/ProgramSummary/Index.
n  Commercial Relationships Index (online only) — This is a 
listing by program number of the commercial relationships and 
names of firms with which commercial relationships exist for 
 
S 320AB
Wednesday, May 07, 2014 8:30 AM-10:15 AM
Physiology/Pharmacology / Glaucoma / Retina
406 Changes in Cell Volume Effecting IOP — 
Minisymposium
4039 — 8:30 Role of aquaporins in cell volume regulation.  
Raj Patil. iVeena LLC, Sandy, UT





Session number Session title
Program number Paper presentation time Paper title
Session location Poster board number range for session
Session day, date and time
Session number Session title
Program number Poster board number for presentation Poster title
Paper Sessions/Symposia/Minisymposia:
*CR refers to the program number in the Commercial Relationships (CR) Index for 
Disclosures. 
 refers to the program number in the Clinical Trial Registration (CT) Index.
Poster board numbers indicate the Exhibit Hall location of the presentation. For example, 
A34 will be located in Poster Area A and C1098 will be located in Poster Area C.
Program information, printing abstracts and other features
For searchable information about the scientific program, authors, printable 
abstracts by session and to develop your own personal Meeting itinerary, visit 
arvo.org/Annual_Meeting/Program.
 Abstracts also will be available at iovs.org, the version of record, in May 
2014. For ARVO abstracts from 2002 forward, the following citation format 
should be used: 
Roska BM, et al. Invest Ophthalmol Vis Sci. 2002;43:ARVO 989.
How to Use the Program Summary 
each First Author and Co-author as indicated. First Authors or 
Co-authors who indicated “none” for commercial relationship  
are not included in this index. See Commercial Relationships 
Policy in the Index. This index can be found online at  
arvo.org/amindices.
Poster Sessions:
Meeting Rooms/Convention Center   
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Check — Wednesday and 
Thursday 
Mothers” Lounge/ 
Meditation Room  
S 219 (key available in  
S 220A)
Meeting Management  




Pizza with an Expert
Breakfast with an Expert
S 210A–C
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ARVO Board of  
Trustees
President
Justine R. Smith, FRANZCO, PhD, FARVO
Immunology & Microbiology
Vice President
John Penn, PhD, FARVO 
Retinal Cell Biology
David R. Williams, PhD, FARVO
Visual Psychophysics & Physiological 
Optics
President-elect
William F. Mieler, MD
Retina
Vice President-elect
Carol B. Toris, PhD, FARVO
Physiology/Pharmacology
Immediate Past President
Sir Peng Tee Khaw, MD, PhD, FARVO
Glaucoma
Executive Vice President
Craig E. Crosson, PhD, FARVO 
Physiology/Pharmacology
Trustees
Sarah E. Coupland, MBBS, PhD, FARVO 
Anatomy/Pathology
Paul S. Bernstein, MD, PhD, FARVO 
Biochemistry/Molecular Biology 
Emily Y. Chew, MD, FARVO 
Clinical/Epidemiologic Research 
Dimitri T. Azar, MD, MBA, FARVO 
Cornea
Linda K. McLoon, PhD, FARVO 
Eye Movements/Strabismus/Amblyopia/
Neuro-Ophthalmology
Claude F. Burgoyne, MD, FARVO 
Glaucoma
John I. Clark, PhD, FARVO 
Lens








Paul P. Lee, MD, JD, FARVO
Immediate Past Chair
Nicolas G. Bazan, MD, PhD, FARVO
Treasurer 
Donald C. Hood, PhD, FARVO
 
Governors
Carlos Belmonte, MD, FARVO
Eric C. Carlson, MD
Steve Charles, MD, FACS, FICS
Cheryl Mae Craft, PhD, FARVO
Julia A. Haller, MD, FARVO
Sabri Markabi, MD
Joan W. Miller, MD, FARVO
Samir C. Patel, MD 
J. Mark Petrash, PhD, FARVO
Paul Sternberg, Jr., MD, FARVO
Joyce Tombran-Tink, PhD, FARVO
Ex Officio to the Governors
Craig E. Crosson, PhD, FARVO
Gary W. Abrams, MD, FARVO
Governor Emeritus — Past Chair
John E. Dowling, PhD, FARVO
Governor Emeritus —- Past Chair
Foundation Staff
Iris M. Rush, CAE
Interim Executive Director














Awards and Grants 
Andrew Dobos
Awards and Grants Senior Manager
Jaya Pothen
Coordinator, Grants




Senior Director, Communications 
and Business Strategies
Katrina Norfleet 
Assistant Director of 
Communications
John Saville 
















   
Information Technology and 
Member Services
Tim Maxey 
Senior Director of Information 
Technology 
Tien Sun 
Director of Database Management
Chaiyanet Sadeewong 














Ashley Engel, CMP 
Meetings Manager
Tia Metzger 




Senior Director of Scientific 
Education
Cathy Conley 














Director, Government Relations and 
Education
Association for Research In Vision and Ophthalmology
1801 Rockville Pike, Suite 400 | Rockville, Maryland 20852-5622
Tel: +1.240.221.2900 | Fax: +1.240.221.0370 | arvo.org
ARVO Foundation for Eye Research
1801 Rockville Pike, Suite 400 | Rockville, Maryland 20852-5622







2014 Annual Meeting Program Committee
Chair
Craig E. Crosson, PhD, FARVO
Medical University of South 
Carolina
Charleston, SC
*CR  — Allmera Sciences (C); Allmera 
Sciences, Lexicon Pharmaceuticals Inc., 
Ocular Services on Demand (OSOD) (F)
Anatomy/Pathology
Tatyana Milman, MD (Chair)
New York Eye and Ear Infirmary
New York, NY
Robert J. Zawadzki, PhD (Chair)
University of California, Davis
Sacramento, CA
Deepak P. Edward, MD
Wilmer Eye Institute/ 
Johns Hopkins University
Baltimore, MD
Ludwig M. Heindl, MD, PhD
University of Cologne
Cologne, Germany
Thomas T. Norton, PhD, FARVO
University of Alabama at 
Birmingham
Birmingham, AL
Rebecca C. Stacy, MD, PhD








Terri L. Young, MD, FARVO
Duke University Eye Center
Durham, NC





Tunde Peto, MD, PhD (Chair)
NIHR Biomedical Research 
Center for Ophthalmology
London, UK
*CR — OPTOS (F)
Susan Vitale, MHS, PhD, FARVO
National Eye Institute/NIH
Bethesda, MD
Alex W. Hewitt, PhD
Centre for Eye Research Australia
Melbourne, Australia
Cornea 
Shiro Amano, MD, FARVO 
(Chair)
University of Tokyo School of 
Medicine
Tokyo, Japan
David A. Sullivan, MS, PhD, 
FARVO (Chair)
Schepens Eye Research Institute/
Harvard Medical School
Boston, MA




Gordon W. Laurie, PhD, FARVO
University of Virginia
Charlottesville, VA
Che John Connon, PhD
University of Reading
Reading, UK
Ula V. Jurkunas, MD







Benjamin Thompson, PhD (Chair)
University of Auckland
Auckland, New Zealand
Vallabh E. Das, PhD
University of Houston
Houston, TX
Howard S. Ying, MD PhD




Jonathan G. Crowston, MBBS, 
PhD (Chair)
Center for Eye Research Australia
Melbourne, Australia
*CR — Alcon, Allergan, MSD, Pfizer 
(C); Allergan (F); Alcon, Allergan, MSD, 
Pfizer (R)
Keith R. Martin, FRCOphth, MD
Cambridge University
Cambridge, UK
Louis R. Pasquale, MD, FARVO
Massachusetts Eye & Ear Infirmary
Boston, MA
Immunology/Microbiology
Andrew W. Taylor, PhD, FARVO 
(Chair)
Boston University School of 
Medicine
Boston, MA
Daniel J. Carr, PhD
University of Oklahoma Health 
Science Center
Oklahoma City, OK
Bahram Bodaghi, MD, PhD, 
FEBO
Pitie - Salpetriere Hospital
Paris, France
*CR — Abbott, Allergan, Novartis, Santen, 
Xoma (C); Allergan, Sanofi, Xoma (F)
Lens
Steven Bassnett, PhD (Chair)
Washington University School of 
Medicine
St. Louis, MO








Julie Sanderson, PhD (Chair)





Caterina Gagliano, MD, PhD




Michael David Abramoff, MD, 
PhD (Chair)
University of Iowa Hospitals & 
Clinics
Iowa City, IA
*CR —  IDx, LLC (C, I, R); Beckman 
Foundation, NIH, RPB, Zoom (F); University 
of Iowa (P)




*CR — Novartis (C, F)




Tel Aviv Medical Center
Tel Aviv, Israel
*CR — Alcon, Alimera, Allergan, Bayer, 
ForsightLabs, Lumenis, Notal Vision, 
Novartis, Orabio, Teva (C, R)
Susumu Ishida, MD, PhD
Hokkaido University Graduate 
School of Medicine
Sapporo, Japan
*CR — Alcon Japan Ltd., Bayer Holding 
Ltd., Keijinkai Maruyama Clinic, Mitsubishi 
Rayon Co., Ltd., Mitsubishi Tanabe Pharma 
Corporation, Nippon Boehringer Ingelheim 
Co., Ltd., Novartis Pharma K.K., Otsuka 
Pharmaceutical Co., Ltd., R-Tech Ueno, 
Santen Pharmaceutical Co., Ltd., Senju 
Pharmaceutical Co., Ltd., Wakamoto Co., 
Ltd. (C); JPY 32,592,000 (P); JPY 765,789 
(P); JPY 825,555 (R)
Srinivas R. Sadda, MD
University of Southern California
Los Angeles, CA
*CR — Allergan, Carl Zeiss Meditec, 
Genentech, Optos (C, F, R)
Retinal Cell Biology





M. Elizabeth Hartnett, MD, 
FARVO
Moran Eye Center, University 
of Utah
Salt Lake City, UT
Commercial Relationship Disclosure Codes Definitions
Category Specific Financial
Code Interests
F  (Financial Support) Indicates if you have received through your employing institution support from a for-profit 
company, or competing company, in the form of research funding, grants or research materials or services 
(e.g., protein sequencing) at no cost, such support being the subject matter of your presentation or publica-
tion.
I  (Personal Financial Interest) Indicates if you are an investor in a company or competing company, other than 
through a mutual or retirement fund, which provides a product, service, process or equipment that is the 
subject matter of your presentation or publication.
E  (Employment) Indicates if you are an employee of a company or competing company with a business interest 
that is the subject matter of your presentation or publication.
C  (Consultant) Indicates if you are, or have been within the last 24 months prior to date of submission, a 
consultant for a company or competing company with a business interest that is the subject matter of your 
presentation or publication.
P  (Patent) Indicates if you are an inventor/developer designated on a patent, patent application, copyright, or 
trade secret, whether or not the patent, copyright, etc. is presently licensed or otherwise commercialized, 
which is the subject matter of your presentation or publication or could be in competition with the technology 
described.
R  (Recipient) Indicates if you have received gifts in kind, honoraria or travel reimbursement valued in any amount 
in the last twelve months from a company or competing company which provides a product, service, process 
or equipment that is the subject matter of your presentation or publication.
N  (No Commercial Relationship) Indicates there is no commercial relationship relevant to the subject matter of 
the abstract/article/presentation.
S  (non-remunerative) Indicates you have position(s) of influence such as officer, board member, trustee, spokes-
person, etc. ARVO considers relationships of the person involved in the CME activity to include financial 
relationships of a spouse or partner, or a dependent child. 
*CR indicates a commercial relationship.  See code and financial relationship 
description in box at left.   See www.arvo.org/amindices for commercial 
relationship descriptions of paper and posters sessions.
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*CR — Owner, AEON Imaging (I)
Susana T. L. Chung, OD, PhD, 
FARVO
University of California, Berkeley
Berkeley, CA 
Rigmor C. Baraas, PhD






*CR — Acufocus, Allergan (C); Alcon, 
Bausch+Lomb, Coopervision (F)
Visual Neuroscience




Wei Li, MD, PhD
National Eye Institute, NIH
Bethesda, MD
Scott A. Nawy, PhD









R. Rand Allingham, MD
Duke University Eye Center
Durham, NC
Douglas B. Gould, PhD
University of California,  
San Francisco
San Francisco, CA
*CR — Gilead Sciences (I)
Low Vision Cross-sectional 
Group
Ava K. Bittner, OD, PhD (Chair)
Nova Southeastern University, 
College of Optometry
Fort Lauderdale, FL
Alexandra R. Bowers, PhD
Schepens Eye Research 
Institute
Boston, MA








David Huang, MD, PhD, FARVO 
(Chair)
Oregon Health & Science 
University
Portland, OR








*CR — Nidek, Tomey Corp, Topcon (F)
Nanotechnology and 
Regenerative Medicine  
Cross-sectional Group





Stowers Institute for Medical 
Research
Kansas City, MO
Christine Frances Wildsoet, OD, 
PhD, FAAO, FARVO
University of California, Berkeley
Berkeley, CA
Uday B. Kompella, PhD, FARVO
University of Colorado, Denver
Aurora, CO
*CR — Bayer, Teva Pharmaceuticals (C); 
Ocugen, Inc. (I); Alcon Research Ltd. (F)
Ex Officio




Sir Peng Tee Khaw, MD, PhD, 
FARVO
NIHR Biomedical Research 
Centre
London, UK
*CR — Alcon, Aquesys (C); Bausch+Lomb, 
Teva Pharmaceuticals (C, R); Lumemed (I); 
Use of matrix metallaproteinase inhibitors 
for prevention of scarring, slow release 
preparations, stem cells for adult eyes (P)
William F. Mieler, MD, FARVO
University of Illinois at Chicago
Chicago, IL
*CR — Allergan, Alcon, Genentech, 
ThromboGenetics (C)
Precision Multi Focal VEP 





Everyone is welcome. Proceeds from the auction 
benefit Women in Eye and Vision Research (WEAVR) 
travel grants. Below are some of the items available:
When: Tuesday, May 6
Where: Level 1, South Exhibit Hall A
Auction bidding: 9:30am – 3:45pm 
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The ARVO/Alcon Keynote Series is 
sponsored by the ARVO Foundation 
through a generous grant from 
Alcon Laboratories.
Keynote Series and Distinguished Service Awards 
Barry Marshall, AC, DSc, FRACP, FRS, FAA
2005 Nobel Laureate, Physiology or Medicine
University of Western Australia
How curiosity-driven research can lead to the  
Nobel Prize
Session #117, Sunday, May 4, 12noon – 1:15pm
Level 1/South Hall B
Jean Bennett, MD, PhD, FARVO
University of Pennsylvania School of Medicine
Seeing the Light with Retinal Gene Therapy: 
Things You Wished You’d Known Early on Your Way 
to Late-Stage Trials
Session #551, Thursday, May 8, 2 – 3:15pm
Level 1/South Hall B
ARVO/Alcon Keynote Series*
ARVO Distinguished Service Awards
Distinguished Service Award recipients will be recognized at the 
General Business Meeting (Session #323, Tuesday, May 6  
10:15 – 10:55am, S 230GH).
Sir Peng T. Khaw, MD, PhD, FARVO
NIHR Biomedical Research Centre
Moorfields Eye Hospital and UCL Institute of 
Ophthalmology
Immediate Past President
Anton M. Kolomeyer,  
MD, PhD
University of Medicine & 




Jacob Pe’er, MD, FARVO
Hadassah-Hebrew University  
Medical Center
Vice President
Sir Peng T. Khaw, 
MD, PhD, FARVO





Martine J. Jager, 
MD, PhD, FARVO
Joanne G. Angle Award 
The Joanne G. Angle Award is the highest service honor to a 
volunteer professional bestowed by ARVO. This award was first 
presented in 2012 posthumously to Joanne G. Angle, ARVO 
executive director for 22 years. 
This 2014 award is presented to Martine J. 
Jager, MD, PhD, FARVO, of Leiden University 
Medical Center in the Netherlands. Among 
her outstanding contributions, Jager served as 
ARVO president (2007 – 2008), Trustee, chair 
of the Annual Meeting Program Committee, 
chair of the Advocacy Committee, chair of the 
International Chapter Affiliate Council and co-
chair of the Long Range Planning Committee. 
In addition, she has served on numerous other committees 
and as an IOVS Editorial Board Member. Jager continues to be 
active in the ARVO Foundation WEAVR Leadership Committee, 
a member of the Dowling Society and has established an ARVO 
travel grant in honor of her father.
The Joanne G. Angle Award will be presented to Jager at the 
General Business Meeting (Session #323, Tuesday, May 6,  
10:15 – 10:55am, Room S 230GH).
Fellows of ARVO
ARVO will induct the Fellows Class of 2014 at the opening  
ARVO/Alcon Keynote Session, to recognize and honor these members 
for their leadership, dedication and contributions to the Association.
Gold Fellows
Dimitri T. Azar, MD, MBA
Bruce A. Berkowitz, PhD
John I. Clark, PhD
Scott W. Cousins, MD
Steven J. Fliesler, PhD
Thomas R. Friberg, MS, MD
John D. Gottsch, MD
David R. Hinton, MD
Gary N. Holland, MD
Marc Kantorow, PhD
Sir Peng Tee Khaw, MD, PhD
Uday B. Kompella, PhD
Friedrich E. Kruse, MD
Geoffrey P. Lewis, PhD
Alexander V. Ljubimov, PhD
David C. Musch, PhD
Joseph F. Rizzo, III, MD
Joel S. Schuman, MD
Janet R. Sparrow, PhD
Kathy K.H. Svoboda, PhD
Silver Fellows
Shiro Amano, MD 
Jayakrishna Ambati, MD
Nancy J. Coletta, OD, PhD
Stephen P. Daiger, PhD
Filippo Drago, MD, PhD
Dan Epstein, MD, PhD
Roderick J. Fullard, PhD, OD
David F. Garway-Heath, MD
David Huang, MD, PhD
Karen M. Joos, MD, PhD
Ordan J. Lehmann, MD, PhD
Jennifer I. Lim, MD
Woo-Kuen Lo
Frank J. Lovicu, PhD
Susana Marcos Celestino
William F. Mieler, MD
Robert F. Miller, MD
Kenneth P. Mitton, PhD
Rajiv R. Mohan, PhD
Vittorio Porciatti, DSc
Graham E. Quinn, MSCE, MD
Thomas W. Raasch, OD, PhD
Leopold Schmetterer, PhD
Marilyn E. Schneck, PhD
Mathias W. Seeliger, MD
K. Krishna Sharma, PhD 
David M. Silver, PhD
Giovanni Staurenghi, MD
Jody A. Summers Rada, PhD
Dora Fix Ventura, PhD
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ARVO Awards and Lectures 
Proctor Award and Lecture
Session #289
Monday, May 5, 5:45 – 6:30pm 
Level 1, South Hall B
Wolfgang Baehr, PhD, FARVO 
University of Utah School of Medicine
Membrane Protein Transport in Photoreceptors
Mildred Weisenfeld Award and Lecture
Session #290
Monday, May 5, 6:45 – 7:30pm
Level 1, South Hall B
José Cunha-Vaz, MD, PhD  
AIBILI, University of Coimbra, Portugal
Phenotypes and biomarkers of diabetic  
retinopathy
Open to established mid-career clinicians and scientists 
whose contributions have advanced vision care and 
vision science and whose further work is expected to 
contribute substantially to the preservation of sight. 
Clinically and/or scientifi cally accomplished, yet under 
recognized in his/her respective fi elds.  
Nominations must be made online.  Please go to 
lighthouseguild.org/bressler.  Closing date for 
nominations and receipt of all supporting documents is 
December 31st, 2014.
The prize of $50,000 will be awarded at the Alfred W. 
Bressler Vision Science Symposium to be held in New 
York City in the fall of 2015.
For additional information call 212-769-7801
or e-mail bressler@lighthouseguild.org
Open to early-career clinicians and scientists, generally 
fewer than ten years following completion of the 
last advanced degree or training, whose noteworthy, 
innovative, and scholarly contributions in vision science 
have the potential  for substantial infl uence on vision 
care and/or vision science.
Nominations must be made online.  Please go to 
lighthouseguild.org/pisart.  Closing date for 
nominations and receipt of all supporting documents is 
December 31st, 2014.
The prize of $30,000 will be awarded at a lecture to be 
held in Florida in the winter of 2015.
For additional information call 212-769-7801
or e-mail pisart@lighthouseguild.org
Formerly Jewish Guild Healthcare 
and Lighthouse International.  
Now twice as strong.
Formerly Jewish Guild Healthcare 
and Lighthouse International.  
Now twice as strong.
2015 Bressler Award in Vision Science 2015 Pisart Award in Vision Science









Cogan Award and Lecture
Session #482
Wednesday, May 7, 5:45 – 6:30pm
Level 1, South Hall B
Kirill Martemyanov, PhD
The Scripps Research Institute
G protein signaling in the retina and beyond
Friedenwald Award and Lecture
Session #483
Wednesday, May 7, 6:45 – 7:30pm
Level 1, South Hall B
Krzysztof Palczewski, PhD
The Scripps Research Institute
Structural biology of the fundamental steps  
in vision






Eye Researcher Travel 
Fellowships
Olga Borodovitsyna
Federal State Institution 
IRTC “Eye Microsurgery” 




Eye Clinic of Kaunas 
Medical Academy 
Hospital Lithuanian 
University of Health 
Sciences  
Kaunas, Lithuanian
Jorge Luis Bustillo 
Gonzalez









Sorocaba Eye Bank - 
Sorocaba Ophthalmology 
Hospital




Department of Pharmacy 
at the  Chemistry Faculty 




















Trinity College Dublin 
Dublin, Ireland
Cristhian J. Ildefonso 
University of Florida 
College of Medicine 
Gainesville, FL
ARVO Foundation/
Ludwig von Sallmann 
Clinician-Scientist 
Award
Balamurali K. Ambati 
John Moran Eye Center 














Hendrik P. N. Scholl




Oberdorfer Award in 
Low Vision 
David B. Rein 





Chicanos and Native 
Americans in Science 
(SACNAS)
Daniel Foster 
University of California, Los 
Angeles 
Los Angeles, CA
   




















Soumyava Basu  









Unit of Clin 
Pharmacokinetics 
Buenos Aires, Argentina
Geeta K Vemuganti 
University of Hyderabad 
Hyderabad, India
Travel Grants
ARVO, the ARVO 
Foundation and our partners 
offer travel grants annually 
to assist young investigators 
in presenting their research 
at the ARVO Annual 
Meeting. Congratulations 
to the following members 
who have been selected to 
receive 2014 Travel Grant 
Awards. The Program 










Brien Holden Vision Institute
Kingsford, NSW Australia
#6065
Celso Henrique Freitas Alves



































































































































































Paulista School of 
Medicine, São Paulo/
Hospital, Federal 
University of São Paulo
São Paulo, Brazil
#3684
See Travel Grants, 
page 16
Recognizing Excellence in Ophthalmic Research
A LCO N  R E S E A R C H  I N S T I T U T E
2013 AwA r d e e s
Gary W. Abrams, MD 
David L. Epstein, MD 
Peng Tee. Khaw, PhD 
Joan W. Miller, MD
Tetsuro Oshika, MD, PhD  
Martin Friedlander, MD 
Dimitri Azar, MD 
Sheila West, PhD 
Henry Edelhauser, PhD 
Emily Chew, MD
Bernhard Weber, PhD
stanley Chang, Md, Chairman
sabri Markabi, Md, secretary 
Scientific Selection Committee Members 
Janey Wiggs, MD, PhD Francois Delori, PhD
Russell Van Gelder, MD, PhD Gustavo Aguirre, VMD, PhDTheodore G. Wensel, PhD
Tin Aung, Mmed, FRCS,  
FRCOphth, PhD
Recognizing Excellence in Ophthalmic Research
A LCO N  R E S E A R C H  I N S T I T U T E
2013 AwA r d e e s
Gary W. Abrams, MD 
David L. Epstein, MD 
Peng Tee. Khaw, PhD 
Joan W. Miller, MD
Tetsuro Oshika, MD, PhD  
Martin Friedlander, MD 
Dimitri Azar, MD 
Sheila West, PhD 
Henry Edelhauser, PhD 
Emily Chew, MD
Bernhard Weber, PhD
stanley Chang, Md, Chairman
sabri Markabi, Md, secretary 
Scientific Selection Committee Members 
Janey Wiggs, MD, PhD Francois Delori, PhD
Russell Van Gelder, MD, PhD Gustavo Aguirre, VMD, PhDTheodore G. Wensel, PhD
Tin Aung, Mmed, FRCS,  
FRCOphth, PhD
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Philipp Herrmann






































































Seoul St. Mary’s hospital 
Eye Institute
(SSEI)
Seoul, Korea, Republic of
#1993
Yimin Li




Jeremiah Kah Heng Lim













Ctr for Eye Research 
Australia

































































































Federal University of  
São Paulo 





















Jaime Javier Soria Viteri
Hospital Dr. Elías Santana









Université de Montréal/  























































Brien Holden Vision 
Institute












European Journal of 
Ophthalmology
Manuela Bossi











Hamilton Eye Institute, 

































Travel Grants, continued 
from page 14
See Travel Grants, 
page 18
A Choice 
In Standardized ETDRS Testing
Good-Lite’s ESV Series Illuminated Cabinets 
Provides Uniform Testing Surface using LED’s
1155 Jansen Farm Drive  •  Elgin, IL  60123




Scan the code for  
more information.
ESC2000
Your choice when cost effective and 
consistent uniform lumination is needed
ESV3000
Your choice when precision calibrated luminance or 
glare lights is a must for your ETDRS Testing.
Awards, Fellowships, Travel Grants and Chapter Affiliates
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Salt Lake City, UT
#3517
Medi Eslani

























Harvard Medical School/ 














Sunday Social  
at Universal Studios Florida® 
Sunday, May 4, 7:30 – 10:30pm
Join your colleagues for food, drinks and 
fun at the New York City Street set at 
Universal Studios. Music is provided by Dr. 
John and ARVO Rocks! on the Universal 
Music Plaza Stage. ARVO attendees 
will have exclusive access to major 
attractions, including Twister...Ride it Out®, 
Transformers: The Ride – 3D, Despicable 
Me Minion Mayhem, Revenge of the 
Mummy® and Hollywood Rip Ride Rockit®. 
 
Student/Trainee Social
Monday, May 5, 7:30 – 9pm 
Hilton Orlando, Fountain Plaza
(6001 Destination Pkwy )
Don’t miss this reception to honor 
students, members-in-training, and travel 
and research grant awardees. Find old 
friends, make 
new ones and 
meet some of 
ARVO’s future 




Wednesday, May 7, 8 – 10pm  
Plaza International Ballroom 
Hyatt Regency Orlando (formerly Peabody)
(9801 International Drive)
The popular ARVO Classical Concert 
is performed by multi-talented ARVO 
members at the beautiful Hyatt Regency 




Wednesday, May 7,  
9pm – 12midnight 
ICEBAR Orlando
(8967 International Drive)
ARVO Karaoke is the chance to showcase 
your vocal talents or cheer on your favorite 
performer. The IceBar Orlando, featured 
as one of the top 10 “Extreme Barhopping” 
bars on Travel Channel, is kept at a frosty 
27 degrees with 50 tons of ice carved into 
a winter wonderland with lights, music and 
the feel of the Antarctic. After your cool 
trek to the bar, warm up in the Fire Lounge 
with ARVO karaoke! Cash bar, light snacks 
and prizes. You must be 21 years or older 
to attend this event.
ARVO social events:  
Everyone is welcome!

























Wilmer Eye Institute,  













Memorial Sloan Kettering 
Cancer Center
New York , NY
#6017
Patrick William Keeley







































































































Vitreous Retina Macula 

















University of Pittsburgh 
Medical Center Eye Center
Pittsburgh, PA
#2648
See Travel Grants, 
page 20
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Hossein Nazari Khanamiri
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ARVO Foundation/  
C. Stephen and 
Frances B. Foster 
Foundation
David D. New

















G. M. Jager 
Monika Ewa Danielewska













IRCSS — Fondazione 
G.B. Bietti per lo 
Studioe la Ricerca in 
Oftalmologia
Fabio Bignami















































































Research Centre for 
Ophthalmology
Jonathan Aboshiha










































Travel Grants, continued 
from page 19
See Travel Grants, 
page 22
Problems Solved - 
• Parallax  errors and frame torsion errors 
are real problems with monocular systems. 
ViewPoint binocular systems eliminate these 
problems providing accuracy over the entire 
range of distance.
•  Systems with fixed cameras and LEDs will 
not work with all eyeware.  Our systems are 
fully adjustable to ensure that they work 
with eyeglasses.
www.ArringtonResearch.com  1.480-985-5810
•	 Light weight and comfortable the eye tracking system can be 
worn without discomfort for long periods.  View real-time gaze or 
recorded AVI 2.0 movies with gaze point shown clearly over the 
scene video.  Easily adjustable in size and compatible with glasses. 
* Compatable with glasses
* Binocular version includes correction for parallax error
* The lightest weight at less than 25g
* No beam splitter
* Wireless Video Monitoring
* No head tracker is required
* Laptop systems available
* Fits any face
ViewPoint EyeTracker ®
New	3DWorkSpace™	 and	3DViewPoint™	 provide	
precise	 3D	 depth	 information	 for	 3D	monitors,	 gaze	
across	multiple	monitors	and	curved	displays.
HeadLock™  & Remote





400 Hz USB 
3DWorkSpace™ 
Leading	 integrator	 of	 HMD	
eye	 tracking	 systems.	 We	 can	
design	for	any	HMD.
HMD Systems
*   Canted / Tilted Displays 
*   Full or Partial Binocular Overlap 
*   See-thru or Opaque Displays 
3DViewPoint™
*   Vergence & Version Angles 
*   3D Scan Paths 
*   Fast & Easy Setup 
*   Intuitive 3D Graphics 
*   Post-hoc ROI Specifications
*   Torsion across 3D Gaze 
*   Heat, Fog and Torch Maps 
*   Polygon/Concave ROI 
*   Angular Calculations
*   Quanternian Transforms
*   MATLAB, Python, etc.
*   SDK
Awards, Fellowships, Travel Grants and Chapter Affiliates
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Travel Grants, continued  
from page 20
Lei Zhang



























Irina De la Huerta
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Moran Eye Center at the 
University of Utah




































Richard Newton Lolley 
Glenn P. Lobo






























Visit NAEVR Central at the ARVO Annual Meeting 
Hours: Sunday – Wednesday, 9am – 4pm
Hosted by NAEVR’s James Jorkasky (left) and David Epstein (right)
•   Contact Congress to support vision research funding increases 
• Learn about research funding resources, such as multiple 
Department of Defense (DOD) funding opportunities to meet critical 
vision research gaps 
NAEVR’s Defense-Related Vision Research 
Opportunities Session
Monday, May 5, 7:30 – 8:30am, S329
NAEVR has invited DOD representatives to speak about FY2014 
funding opportunities and past DOD awardees to offer insights into 
how researchers can be most responsive to the funding Program 
Announcement. 
eyeresearch.org





































The Massachusetts Eye 














Visión y Oftalmologia 
(AIVO)
Melina Bordone







Juan Pablo Real Sr











ARVO Eygpt  
(ARVO-Egypt)
Azza Abdelfattah Shehab
El Watany Eye Hospital 
Cairo, Egypt
Maged Maher Salib 
Roshdy




Research in Vision 
and Ophthalmology 
(BRAVO)
Carolina dos Santos Araújo








de Investigación en 
Ciencias Visuales – 
Mexico (MARVO)















University of Debrecen 
Debrecen, Hungary
Eszter Szalai
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POWERFUL CONNECTIONS: VISION 
RESEARCH AND ONLINE NETWORKING
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Boglárka Enikö Varga 
Semmelweis University 
Budapest, Hungary
Indian Eye Research 
Group – ARVO  
(IERG – ARVO)
Praveen Kumar Balne 
LV Prasad Eye Institute 
Hyderabad, India
Israel Society for 
Vision and Eye 





The Maurice and Gabriela 
Goldschleger Eye 
Research Institute; 
Sheba Medical Center 
Tel-Hashomer, Israel
Adi Hanuka
Department of Electric 
Engineering, Technion-






























ARVO would like to recognize and honor the members that we lost in 2013 and 2014.  
We’re proud of our members and their contributions to ARVO and the vision and eye research community.  If you know of a member that 
has passed away, please let us know, arvo.org/submitobit.
Aug. 28, 2013 
Bernard Becker, MD, FARVO  
Washington University School of Medicine
St Louis, MO 
GL Section, 1966 ARVO President
1958 Friedenwald Awardee
1980 Proctor Medal Awardee
1995 Weisenfeld Awardee
March 26, 2013
Chandler Dawson, MD, FARVO 




David L. Epstein, MMM, MD
Duke Eye Center
Durham, NC 27710
GL Section, 1992–1993 ARVO President
2013 Weisenfeld Awardee
Oct. 9, 2013
James M. Hill, PhD, FARVO      
Louisiana State University
Health Sciences Center
New Orleans, LA 
IM Section
June 1, 2013





Sept. 22, 2013 





VN Section, 1975 Friedenwald Awardee
June 19, 2013 
Raili Kerppola, MBA, PhD
ONL Therapeutics
Ann Arbor, MI 
RE Section
May 1, 2013 











Department of Ophthalmology 
University of Florida
Gainesville, FL
RE Section, 1979 ARVO President
April 29, 2013
Stephen J. Ryan, Jr., MD, FARVO      
Doheny Eye Institute
Los Angeles, CA 
RE Section, 1993 – 2013 NAEVR President
1988 Kupfer Awardee
March 17, 2014
Ronald E. Smith, MD, FARVO
Doheny Eye Institute
Los Angeles, CA 
IM Section, NAEVR Board Member
June 4, 2013 
Ramesh C. Tripathi
University of South Carolina
Columbia,  SC
GL Section
The objective of the 2014 Annual Meeting is to provide a forum for the 
exchange of new ophthalmology and vision research by scientists and 
investigators.
2014 Annual Meeting Accreditation Information
The Association for Research in Vision and Ophthalmology (ARVO) 
is accredited by the Accreditation Council for Continuing Medical 
Education (ACCME) to provide continuing medical education for 
physicians.
ARVO designates the 2014 Annual Meeting, a live activity, for a 
maximum of 22.5 AMA PRA Category 1 Credits™. Physicians 
should claim only the credit commensurate with the extent of their 
participation in the activity. 
The following 2014 Annual Meeting formats are not eligible for AMA 
PRA Category 1 Credit™: ALCON/Keynote series, Award Lectures, 
Posters, Workshops, Special Interest Groups (SIGs), and the 
Research Grant Administrators Program. See the list of CME eligible 
sessions for more details. 
ARVO designates live full-day Education Courses, for a maximum 
of  6.5 AMA PRA Category 1 Credits™ and live half-day Education 
courses for a maximum of 3.5 AMA PRA Category 1 Credits™. 
Physicians should claim only the credit commensurate with the extent 
of their participation in these activities. 
Education courses that are eligible for AMA PRA Category 1 Credit™ 
include: New Insights in Understanding Diabetic Retinopathy; 
Predicting, Measuring and Treating Changes in Corneal Biomechanics; 
and Telehealth Methods for Eye Disease: Focus on Diabetic 
Retinopathy, Glaucoma and Retinopathy of Prematurity.
The AMA has determined that physicians not licensed in the USA who 
participate in this CME activity are eligible for AMA PRA Category 1 
Credit™.
Professional Practice Gap and Needs Statement
Clinicians need access to the most current research in ophthalmology 
and vision science in order to learn more about cellular functions 
within the eye and new pre-clinical possibilities. Exposure to this new 
information will enhance the clinician’s understanding of eye and vision 
disease processes to the benefit of their patients. 
Competencies
This activity was planned in the context of the following IOM/ACGME 
competencies: Medical Knowledge, Systems Based Practice, Working 
as part of Interdisciplinary Teams, and Practicing Evidence-based 
Medicine. 
Target Audience
The Annual Meeting is targeted to clinical practitioners, research 
scientists, and medical education professionals involved in 
ophthalmology and vision research and treatment. 
Learning Objectives
Upon participation in this activity, attendees will be able to:
n Discuss the ophthalmology and vision research underway relevant 
to their areas of interest
n Describe the methods being used by researchers and practitioners 
in these fields
n Integrate the discovery of new methods/ideas into one’s own 
practice
Disclosure Policy 
It is the policy of ARVO to ensure balance, independent objectivity, and 
scientific rigor in all its sponsored educational programs. All persons 
in a position to control the content of a continuing medical education 
activity are required to disclose to ARVO and the program audience 
any relevant commercial relationships held within the past 12 months 
by themselves, their spouses, and/or their partners. The disclosure 
must include the name of the commercial interest and the nature of 
the relationship. The Continuing Medical Education Committee reviews 
each disclosure for real and potential conflicts of interest and removes 
sessions from the CME program if conflicts are identified. See the 
ARVO Commercial Relationships Policy on the first page of the 
Commercial Relationships Index for more details. 
Evaluation/CME Certificate and Certificate of Attendance 
CME Certificates for attending CME-eligible sessions and Certificates 
of Attendance are accessible via ARVO’s online evaluation system at 
http://www.planion.com/Web.Admin/Login?Account=ARVO. All 
evaluations and requests for credit should be entered into the system 
by 12 midnight EST, on Monday, September 1, 2014.
Attendees who preregistered for the Education Courses by Monday, 
April 28, 2014, can submit evaluations starting Saturday, May 3, 2014. 
Those who preregister for the Annual Meeting by Monday, April 28, 
can submit evaluations starting on Sunday, May 4. All others may 
access the system beginning Wednesday, May 14, 2014. Use your 
ARVO ID and Password, or click “forgot your password” to log in. 
Certificates are official. You will not receive additional documentation. 
You may log on to update record/print certificate(s) anytime. 
Questions? Email: education@arvo.org 
Disclaimer 
The Annual Meeting provides a forum for the open exchange and 
discussion of research results and scientific advancements in the field 
of ophthalmology. ARVO makes no representation or warranty as to 
the truth, originality, or accuracy of the information presented at the 
meeting or in materials distributed in connection with it. The views 
expressed by the individual speakers are not necessarily the views of 
ARVO. ARVO supports the ACCME’s policy on evidence-based content 
and encourages faculty to adhere to these standards when planning a 
presentation.
Contact information
Any questions related to CME may be directed to ARVO staff at 
education@arvo.org
 Continuing Medical Education Credits
 Continuing Medical Education Sessions
Certificates of Attendance and Annual Meeting Evaluations will be available online at arvo.org/cme after the Annual Meeting. Certificates can 
be updated/printed at any time. Questions? Email: education@arvo.org.  The following sessions of the ARVO 2014 Annual Meeting are eligible 
for CME: 
Session # Session Title
163 Basic/Clinical Lecture: From Bench to Therapy: Translating 
Molecular Genetics into Clinical Practice
202 ipRGCs
206 Mechanisms of Axonal Damage in Optic Nerve Disease 
209 Myopia — going beyond the near-work hypothesis
210 Functional, Evolutionary and Translational Genomics
230 New ideas in glaucoma
231 Anterior segment problems in world-wide populations
232 Non-Coding Variations of the Genome and Their Alterations in 
Ocular Disease
233 The fiber cell environment
234 Corneal Infection and Inflammation
249 Exomes and Eye Disease — Challenges and Successes
268 Targets for Neurodegeneration and Neuroprotection
269 Molecular mechanisms of AMD
303 New Perspectives on Color Vision
304 Eye movements
306 Stem Cells: Biology and Therapeutic Applications
307 Life-and-death consequences of visual impairment
308 Mechanisms in retinal degeneration
328 Mechanisms in retinal angiogenesis and retinopathy
330 Phototransduction
331 Myopia
333 The Microbiome of the Eye and Beyond — How the 
Microbiome Influences Resistance against Opportunistic 
Pathogens 
351 Binocular Vision Meets Low Vision
364 Leading Edge — New Directions in the Analysis of Retinal 
Image Motion 
367 Neuro-ophthalmology
371 Lens cell survival, development, and aging
372 Inflammatory Tissue Damage and Immunoregulation
402 AMD Imaging and Phenotyping
405 Retinal Development
408 Crystallins: form and function
409 Hot topics in infection and immunity




431 Biomechanics and blood flow
432 RPE Cell Biology
433 New Developments in Ophthalmic Genetics
435 Retinopathy of Prematurity
436 Current Topics in Anatomy
438 Ocular Immune Responses
439 Corneal stoma and wound repair
463 Retinal degeneration and treatment
466 Protein Function in Glaucoma
467 Lens genetics and gene expression
525 Photoreceptors
528 Visual Development and Amblyopia
530 Fundamental Mechanisms of Retinal Diseases
532 Age-Related Macular Degeneration — What puts you at risk?
533 Protein Interactions and Trafficking
535 Cataractogenesis
537 Application of molecular biology to corneal regenerative 
medicine
Chair
Bennie H. Jeng, MD




Karen M. Joos, MD, PhD, FARVO
Vanderbilt University
Nashville, TN
*CR — Vanderbilt University (P)
Members
Esen K. Akpek, MD
Wilmer Eye Institute, Johns Hopkins 
University Medical Center
Baltimore, MD





Shashi D. Ganti, MBA, MD
Porterville, CA
Judy E. Kim, MD
Medical College of Wisconsin
Milwaukee, WI
*CR — ThromboGenics (C) 
Marlyn P. Langford, PhD




Schepens Eye Research Institute
Boston, MA
Samuel C. Yiu, MD, PhD




Craig E. Crosson, PhD, FARVO
Medical University of South Carolina
Charleston, SC
*CR — Allmera Sciences (C); Allmera 
Sciences, Lexicon Pharmaceuticals Inc., 
Ocular Services on Demand (OSOD) (F)
Sir Peng Tee Khaw, MD, PhD, FARVO
NIHR Biomedical Research Centre
London, UK
*CR — Alcon, Aquesys, Bausch+Lomb, 
Teva Pharmaceuticals (C); Lumemed (I); 
Use of matrix metallaproteinase inhibitors 
for prevention of scarring, slow release 
preparations, stem cells for adult eyes (P) 
Bausch+Lomb, Teva Pharmaceuticals (R)
William F. Mieler, MD, FARVO
University of Illinois at Chicago
Chicago, IL
*CR — Allergan, Alcon, Genentech, 
ThromboGenetics (C)
Trustee Liaison
Justine R. Smith, MBBS, PhD, FARVO
Flinders University
Bedford Park SA, Australia
*CR indicates a commercial relationship.  See code and financial relationship description in box on 
page 8. See www.arvo.org/amindices for commercial relationship descriptions of paper and posters 
sessions
CME Committee Members and Disclosures
